Inhibrx Biosciences, Inc.

INBX Nasdaq CIK: 0002007919

Company Information

Industry Biological Products, (No Diagnostic Substances)
SIC Code 2836
Entity Type operating
SEC Category Emerging growth company
State of Incorporation DE
Business Address 11025 N. TORREY PINES ROAD, SUITE 140, LA JOLLA, CA, 92037
Mailing Address 11025 N. TORREY PINES ROAD, SUITE 140, LA JOLLA, CA, 92037
Phone (858) 795-4220
Fiscal Year End 1231
EIN 990613523

Financial Overview

FY2025

$180.77M
Total Assets
$152.60M
Cash & Equivalents

Recent SEC Filings

Form Type Date Filed Document
8-K Current report of material events March 19, 2026 View on SEC
10-K Annual financial report March 19, 2026 View on SEC
8-K Current report of material events February 23, 2026 View on SEC
SCHEDULE 13G/A Passive ownership amendment February 17, 2026 View on SEC
SCHEDULE 13G Passive beneficial ownership (>5%) February 11, 2026 View on SEC
SCHEDULE 13G Passive beneficial ownership (>5%) January 21, 2026 View on SEC
8-K Current report of material events December 16, 2025 View on SEC
10-Q Quarterly financial report November 14, 2025 View on SEC
8-K Current report of material events November 14, 2025 View on SEC
8-K Current report of material events October 23, 2025 View on SEC

Annual Reports

10-K March 19, 2026
  • Inhibrx Biosciences (INBX) is focused on discovering and developing new biologic medicines through early research and human trials.
  • The company demonstrates transparency by proactively adopting new accounting rules faster than required for an Emerging Growth Company (EGC).
View Analysis

Related Companies

Companies in the same industry (SIC: 2836)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.